Thu 25 Jun 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| Arava® -leflunomide | Risk of serious birth defects when administered during pregnancy<strong> </strong><strong></strong> |
||
| Methotrexate "Ebewe” | Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE &quot;EBEWE “ for autoimmune diseases |
||
| Roaccutne | Roaccutne (isotretinoin): An update on neuropsychiatric disorders. |
||
| soliqua (lixisenatide /insuline glargin) soliqua | (lixisenatide /insuline glargin): Important information on dosing. |
||
| Gilenya (fingolimod) | Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception. |
||
| Advaquin ( levofloxacin) | Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection. |
||
| Darzalex (Daratumumab) | Darzalex (Daratumumab): New identified risk of hepatitis B reactivation. |
||
| Lemtrada® Alemtuzumab | Alemtuzumab (Lemtrada): New safety information. |
||
| Apixaban, Edoxaban, Dabigatran and Rivaroxaban | Direct Healthcare Professional Communication (DHPC) for the Direct Oral Anticoagulants (DOACs) Apixaban, Edoxaban, Dabigatran and Rivaroxaban. |
||
| blinatumomab | Blincyto (pembrolizumab): Risk of Medication Errors and Benzyl alcohol toxicity. |
Last update date: 21/04/2024 at 10:00 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.